Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04135807 · ClinicalTrials.gov registry record · Early Phase 1
Implantable Microdevice In Primary Brain Tumors
A Early Phase 1 study of Glioblastoma and Astrocytoma, sponsored by Oliver Jonas.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04135807 is a Early Phase 1 study of Glioblastoma and Astrocytoma that is actively recruiting participants, run by Oliver Jonas. The registered enrollment target is 12 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04135807, a Early Phase 1 study of Glioblastoma and Astrocytoma, is actively recruiting participants, sponsored by Oliver Jonas.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors. * The device involved in this study is called a microdevice. * The drugs used in this study will only include drugs already used systemically for the treatment of gliomas.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Microdevice
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-03-03 |
| Est. Completion | 2028-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04135807
The ClinicalTrials.gov registry entry for NCT04135807 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (89% lower). The listed sponsor is Oliver Jonas, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Microdevice is the first listed.
NCT04135807 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04135807 about?
NCT04135807 is a clinical study titled "Implantable Microdevice In Primary Brain Tumors". This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors. * The device involved in this study is called a microdevice. * The drugs used in this study...
What is the current status of trial NCT04135807?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2020-03-03. Estimated completion is 2028-06-01.
What conditions does trial NCT04135807 study?
This clinical trial studies the following conditions: Glioblastoma, Astrocytoma, Anaplastic Oligodendroglioma, Grade II Glioma, Grade III Glioma.
What interventions are being tested in trial NCT04135807?
The interventions under investigation include: Microdevice (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04135807?
This trial is sponsored by Oliver Jonas, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04135807 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
-
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.